Company Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Two Year Follow-Up Published on EU Scleroderma Trial

Cytori Therapeutics Inc (NASDAQ:CYTX) announced publication of two-year clinical follow-up of patients treated with a single administration of ECCS-50 in the SCLERADEC-I pilot trial of Cytori Cell Therapy in patients with hand dysfunction associated with scleroderma. The results, published by Dr. Brigitte Granel and colleagues of the Assistance Publique des Hôpitaux de Marseille, were published in the journal Current Research in Translational Medicine.

The authors report that key clinical benefits reported at the 6-month time point of the trial were sustained at two years (follow up range of 22–30 months). The primary endpoint, Cochin Hand Function Score improved 62.5% over baseline (18.6±13.8 at two years vs. 48.5±10.8; p<0.0001).  Key secondary endpoints also improved from baseline. Specifically, pain was reduced from 59.4±17.2 at baseline to 29.5±25.2 at two years (p=0.02), scleroderma-associated disability was reduced by 51.1% (0.7±0.5 vs. 1.4±0.3; p=0.0051), and Raynaud’s Condition Score improved by 88.3% (0.8±0.9 vs. 7.2±0.9; p<0.0001).

In addition, key objective measures of scleroderma hand involvement showed sustained benefit: digital ulcers remained reduced from baseline by 60% (6 vs. 15 at baseline) and improvement in pinch strength was also sustained. Trends indicating improvement in hand mobility were also reported. An interesting finding noted by the authors was that eight patients who had been treated previously with prostanoids had not required subsequent re-treatment with these agents in the two year follow up period.

“The long-term follow data from this small, open label trial, continues to suggest that a single administration is safe and may provide long term benefits across multiple scleroderma symptoms,” said Dr. Marc H. Hedrick, M.D., Cytori’s President & Chief Executive Officer. “Scleroderma is a very complex disease but shares common features with other connective tissue disorders that may be attractive future targets for the therapy.”

The SCLERADEC I trial was a 12 patient, single arm, open label study led by Drs. Brigitte Granel and Guy Magalon of APHM supported by the team of Pr. Florence Sabatier of the Cell Therapy Department of Hôpital de le Conception, Assistance Publique-Hôpitaux de Marseille. (Original Source)

Shares of Cytori Therapeutics closed yesterday at $1.56, down $0.06 or -3.70%. CYTX has a 1-year high of $5.91 and a 1-year low of $1.50. The stock’s 50-day moving average is $1.93 and its 200-day moving average is $2.17.

On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on CYTX, with a price target of $5, in a report issued on November 15. The current price target represents a potential upside of 221% from where the stock is currently trading. According to, Kolbert has a yearly average loss of 14.3%, a 28% success rate, and is ranked #4151 out of 4239 analysts.

Cytori Therapeutics, Inc. is a late stage cell therapy company. Its develops autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts